AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 71 min read$GRAL

Freidin Aaron sold $3.5M of GRAL

Freidin Aaron (Chief Financial Officer) sold 23,619 shares of GRAIL, Inc. (GRAL) at $146.39 ($3.46M total) on 2026-10-05.

Original reporting
SEC EDGAR · Freidin Aaron
Published Oct 7, 2026, 10:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 10:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$GRAL
Bearish
high confidence
Mentioned
$GRAL
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GRALBearishLow
01

Why it matters

The CFO's sale reduces insider ownership, potentially prompting short‑term selling pressure.

02

Market read

Primary insider sale news; modest but actionable for short‑term traders.

03

What to watch

No 10b5‑1 plan; the CFO may need liquidity for personal reasons.

Relevance 6/10Novelty 7/10Timing: post‑filing today

Background

Form 4 disclosures provide transparent reporting of insider transactions required by the SEC.

Company-level read

Ticker impact

$GRALBearishHigh confidence
Context

CFO Aaron Freidin sold 23,619 shares for $3.46M, reducing his stake to 225,364 shares.

Expected impact

likely downward pressure as the market prices in the insider sell

Evidence & confidence

Form 4 filings are primary source disclosures; a CFO selling multi‑million dollars is material and often interpreted as a negative signal.

Market effects

Sector

Minimal impact on the broader biotech sector; isolated to GRAL.

Regional

U.S. market may see slight dip in GRAL shares.

Global

Low

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing, not a confidence issue.

Key entities

  • company
    GRAIL, Inc.

    Biotech firm developing early cancer detection tests.

  • person
    Aaron Freidin

    Chief Financial Officer of GRAIL.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

GRAL insider trading history →

Related articles

OCT 3
$GRALHighAI 8/10

Why GRAIL (GRAL) Is Up 8.1% And What's Next After Galleri FDA Backing

GRAIL (GRAL) shares rose 8.1% after an FDA advisory panel backed its Galleri blood test, citing strong clinical data. The test showed 99.64% specificity and 60.3% positive predictive value in detecting early-stage cancers. The company projects $348.4M revenue and $60.1M earnings by 2029, but analysts warn of reimbursement risks and high cash burn.

simplywall.st3 min
SEP 30
$GRALHighAI 8/10

Grail Stock Has Soared 180% in 6 Months. Here's Why the Stock Has More Room to Run.

Grail's (GRAL) stock rose after an FDA advisory committee voted favorably on its Galleri test. The test, already available, needs insurer coverage for growth. FDA approval, likely following the vote, could prompt insurer evaluation. Insurers will assess cost-effectiveness and clinical utility. Grail's data shows Galleri's potential in detecting 12 deadly cancers.

aol.com2 min
SEP 30
$IOVAMedAI 8/10

Biotech Stocks At 52-Week Highs - IOVA +31%, XERS, GRAL, ABCL, SGHT

Several biotech stocks hit 52-week highs on September 29, 2026. Iovance (IOVA) rose 31% to $11.17, raising its revenue guidance to $410M-$420M. Xeris (XERS) reached $11.33, with updates on its XP-8121 program. AbCellera (ABCL) peaked at $14.82, with positive Phase 2 results for ABCL635. Grail (GRAL) hit $140.88 after FDA panel support for its Galieri test. Sight Sciences (SGHT) climbed to $9.71, reporting $23M in Q2 revenue, up 20% YoY.

rttnews.com2 min